Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOT102 in pancreatic adenocarcinoma
NCT05525286Phase 2Terminated
- Sponsor
- SOTIO Biotech
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of SOT102 in pancreatic adenocarcinoma (PDAC), sponsored by SOTIO Biotech. Started Mar 2022; status: terminated.
02
Drugs
SOT102
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05525286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525286.